Metabolic adaptation drives arsenic trioxide resistance in acute promyelocytic leukemia. by Balasundaram, N et al.
American Society of Hematology
2021 L Street NW, Suite 900,
Washington, DC 20036
Phone: 202-776-0544 | Fax 202-776-0545
bloodadvances@hematology.org
Metabolic adaptation drives arsenic trioxide resistance in acute promyelocytic
leukemia
Tracking no: ADV-2021-005300R1
Nithya Balasundaram (Christian Medical College, India) Saravanan Ganesan (Inserm UMR-S1131, Université
de Paris, IRSL, Hôpital Saint-Louis, France) Ezhilarasi Chendamarai (Christian Medical College, India)
Hamenth Palani (Christian Medical College, India) Arvind Venkatraman (Christian Medical College, India)
Ansu Abu Alex (Christian Medical College, ) Sachin David (Christian Medical College, Vellore - 632004,
India) Swathy Palanikumar (Christian Medical College, India) Nair Reeshma Radhakrishnan (Christian
Medical College, India) Mohammed Yasar M (Christian Medical College, India) Sanjeev Krishna (St.George's
University of London, United Kingdom) Anu Korula (CHRISTIAN MEDICAL COLLEGE AND HOSPITAL VELLORE, India)
Uday Kulkarni (Christian Medical College, India) Nancy Janet (Christian Medical College, India)
Poonkuzhali Balasubramanian (Christian Medical College, India) Vikram Mathews (Christian Medical
College, India) 
Abstract:
Acquired genetic mutations can confer resistance to arsenic trioxide (ATO) in the treatment of acute
promyelocytic leukemia (APL). However, such resistance-conferring mutations are rare and do not explain
most disease recurrence seen in the clinic. We have generated stable ATO-resistant promyelocytic cell
lines that are also less sensitive to ATRA and the combination of ATO and ATRA compared to the sensitive
cell line. Characterization of these in-house generated resistant cell lines showed significant
differences in immunophenotype, drug transporter expression, anti-apoptotic protein dependence, and PML-
RARA mutation. Gene expression profiling revealed prominent dysregulation of the cellular metabolic
pathways in these ATO resistant APL cell lines. Glycolytic inhibition by 2-DG was sufficient and
comparable to the standard of care (ATO) in targeting the sensitive APL cell line. 2-DG was also
effective in the in vivo transplantable APL mouse model; however, it did not affect the ATO resistant
cell lines. In contrast, the resistant cell lines were significantly affected by compounds targeting the
mitochondrial respiration when combined with ATO, irrespective of the ATO resistance-conferring genetic
mutations or the pattern of their anti-apoptotic protein dependency. Our data demonstrate that the
addition of mitocans in combination with ATO can overcome ATO resistance. We further show that this
combination has the potential in the treatment of non-M3 AML and relapsed APL. The translation of this
approach in the clinic needs to be explored further.
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 Metabolic rewiring promotes ATO resistance in APL, independent of PML mutation 
status. 
 Inhibiting mitochondrial respiration in combination with ATO can be used as a 
potential therapeutic option for relapsed APL and non-M3 AML. 
 
Abstract: 
Acquired genetic mutations can confer resistance to arsenic trioxide (ATO) in the 
treatment of acute promyelocytic leukemia (APL). However, such resistance-conferring 
mutations are rare and do not explain most disease recurrence seen in the clinic. We 
have generated stable ATO-resistant promyelocytic cell lines that are also less sensitive 
to ATRA and the combination of ATO and ATRA compared to the sensitive cell line. 
Characterization of these in-house generated resistant cell lines showed significant 
differences in immunophenotype, drug transporter expression, anti-apoptotic protein 
dependence, and PML-RARA mutation. Gene expression profiling revealed prominent 
dysregulation of the cellular metabolic pathways in these ATO resistant APL cell lines. 
Glycolytic inhibition by 2-DG was sufficient and comparable to the standard of care 
(ATO) in targeting the sensitive APL cell line. 2-DG was also effective in the in vivo 
transplantable APL mouse model; however, it did not affect the ATO resistant cell lines. 
In contrast, the resistant cell lines were significantly affected by compounds targeting 
the mitochondrial respiration when combined with ATO, irrespective of the ATO 
resistance-conferring genetic mutations or the pattern of their anti-apoptotic protein 
dependency. Our data demonstrate that the addition of mitocans in combination with 
ATO can overcome ATO resistance. We further show that this combination has the 
potential in the treatment of non-M3 AML and relapsed APL. The translation of this 














Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia 
(AML) characterized by the presence of reciprocal translocation between the PML gene 
on chromosome 15 and the retinoic acid receptor α (RARα) gene on chromosome 17 
[t(15;17)], resulting in the production of a chimeric and novel PML-RARα fusion 
oncoprotein that leads to the differentiation block of promyelocytes to mature 
granulocytes1. Combination therapy of arsenic trioxide (ATO) and all-trans-retinoic acid 
(ATRA)2-4 in the management of APL has significantly improved survival rates 
compared to either administered as single agents or a combination of ATRA with 
chemotherapy5-7.  
We recently reported on the mutational spectrum of relapsed and newly 
diagnosed APL patients and demonstrated the importance of additional genetic events 
(FLT3, KRAS, NRAS, ARID1B, p53, and WT1) during disease recurrence.  However, it 
was also noted that mutations resulting in primary or secondary ATO resistance are 
extremely rare and could not explain the majority of disease relapses8. Other 
mechanisms such as bone marrow microenvironment mediated drug resistance, up-
regulation of anti-apoptotic factors, modulation of cellular energy metabolism, and 
oxidative stress could potentially contribute to therapy resistance.   
Existing literature on ATO resistance in APL has focused on the presence / 
acquisition of PML B2 domain mutations, with evidence supporting the presence of 
genetic mutations in the PML B2 domain (C212-S220; A216V) conferring resistance to 
ATO in APL. These mutations alter or inhibit ATO binding to the B2 domain of the PML 
component of the PML-RARA oncoprotein9-13. However, such acquired somatic 
mutations are rarely seen in the clinic and cannot explain the relapses that occur in 
patients treated with ATO based regimens. Additionally, in APL, unlike the other 
subtypes of AML, there is little evidence to suggest the existence of a leukemic stem 
cell population to explain disease recurrence14.  
Recent observations and studies report the novel mechanism of action of ATO 
such as promotion of non-classical apoptosis (ETosis: extracellular DNA traps )  in a 
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and Cys704 residues in hexokinase 2 (HK2) and pyruvate kinase (PKM2) reducing the 
enzymatic activity of these proteins and acts as glycolytic inhibitor16. It has further been 
demonstrated that this glycolytic inhibition is an important mechanism by which it 
promotes apoptosis in cancer cells and over expression of HK2 significantly rescued the 
cells from ATO induced apoptosis16-18. These observations further illustrate that the 
mechanisms of action of ATO are complex and multi-factorial, suggesting that 
mechanisms of resistance are also likely to be varied.  
To further interrogate the mechanisms of ATO resistance we generated and 
characterized a stable ATO resistant cell line with the objective of finding potentially 




Cell lines and chemicals:  
The human APL cell line NB4 was a kind gift from Dr. Harry Iland, RPAH, 
Sydney, Australia, with permission from Dr. Michel Lanotte. In addition to the in house 
generated ATO resistant cell lines, we also used an ATRA resistant APL cell line UF1 (a 
kind gift from Dr. Christine Chomienne, Hôpital Saint Louis, Paris). The cell lines were 
free from mycoplasma contamination (Universal Mycoplasma Detection Kit, ATCC 
Manassas, VA, USA).  Primary cells were obtained after getting written and 
informed consent (IRB No: 5884). Arsenic trioxide was a kind gift from INTAS 
Pharmaceuticals, Ahmedabad, India. 2-NBDG – fluorescent analog of D-Glucose, JC-1 
and 2- Deoxy Glucose (2-DG), Carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone -
FCCP were purchased from Sigma Aldrich (Sigma Aldrich, St Louis, MO, USA). 
 
Exome sequencing:  
Genomic DNA was isolated from the naïve NB4 cells and the ATO resistant NB4 
sub clones NB4-EVAsR1 and UF1 using Gentra puregene blood kit (Qiagen, Hilden, 
Germany) and stored at 4°C. Library preparation and sequencing were performed at 
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Exome Enrichment for the Ion Proton™ System, sequencing was performed on Ion 
Proton™ sequencer. The mutations were confirmed by Sanger sequencing. 
 
Chromatin-immunoprecipitation sequencing (ChiP-Seq): 
 H3K27ace pull down was performed using simpleChIP® Enzymatic Chromatin 
IP Kit as per the manufacturers protocol (Cell signaling Technology, MA, USA). ChIP-
Seq data was generated from two independent experimental replicates. Total genomic 
DNA (input) derived from formaldehyde cross-linked samples was used as control 
during peak calling. Raw sequence reads that passed quality control were aligned to the 
human reference genome (available from the UCSC genome browser, 
http://genome.ucsc.edu/). Peak calling on all ChIP-Seq data was performed using 
MACS v2.1.  
 
Gene expression array and analysis:  
A global gene expression array for differential gene expression in naïve NB4 
cells and the ATO resistant NB4 primary resistant clone was performed. 2x107 cells 
(NB4 naïve, NB4EV-AsR1, and UF1) were harvested and stored in RNA later solution. 
The extracted labeled RNAs were hybridized to Agilent Human Whole Genome 8x60K 
Gene Expression Array (AMADID: 039494), and the Image analysis was done using 
Agilent Feature Extraction software Version 10.5.1.1 to obtain the raw data. 
Normalization and statistical analysis of the microarray data were done using 
GeneSpring GX (Agilent Technologies, CA, USA). Differentially regulated genes were 
clustered using hierarchical clustering to identify significant gene expression patterns 
Genes were classified based on functions and pathways using biological interpretation 
tool Biointerpreter (Genotypic Technology, Bangalore).  
 
Seahorse extracellular flux analysis:  
Extracellular flux assay kit XF24 (Agilent Technologies, CA, USA) was used to 
measure oxygen consumption rate and glycolytic flux. Briefly, three replicate wells of 
5 x 104 cells per well were seeded in a retronectin (Takara Bio Inc, JPY) coated 24-well 
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media (Agilent Technologies, CA, USA), and the plate was incubated at 37 °C. Analyses 
were performed both at basal conditions and after injection of glucose, oligomycin, and 
2-deoxy glucose for glycolytic function.  
 
Mouse model and drug treatments:  
FVB/N mice were obtained from Jackson Laboratory (Bar Harbor, ME, USA). 
Mice at 6 to 8 weeks of age were used in all the experiments. The animal study design 
and euthanasia protocols were approved by the institutional animal ethics committee 
(IAEC approval number 04/2019). APL cells from the spleen of MRP8-PML-RAR 
transgenic mice (FVB/N) were harvested and cryopreserved (a kind gift from Dr. Scott 
Kogan, UCSF, USA). APL cells (106 cells/mouse) were injected intravenously via the tail 
vein into genetically compatible FVB/N recipients, without conditioning. After the 
leukemic cell engraftment period (day 8), intraperitoneal injection of ATO (10mg/Kg) and 
2-DG (750mg/Kg) was administered for 15 days.  
 
Intracellular BH3 (iBH3) profiling:  
106 cells/mL were suspended in BH3 profiling buffer, digitonin permeabilized and 
exposed to pro-apoptotic peptides at a concentration of 20µM (Bim, BAD, HRK and MS-
1, GenScript, New Jersey, United States) for 90minutes. We then proceeded according 
to the standardized protocol from the Anthony Letai laboratory (http://letailab.dana-
farber.org/bh3-profiling.html) to measure intracellular retention of cytochrome c. After an 
overnight incubation with anti-Cytochrome-c (6H2.B4)-FITC antibody (BioLegend, CA, 
USA) the cells were acquired on a flow cytometer (Beckman Coulter Navios, Brea, CA, 
USA). Loss of cytochrome-c is proportional to the priming status of the mitochondria 
and its anti-apoptotic dependency by their peptide specificity. 
 
Statistical Analysis:  
All statistical analyses were carried out using GraphPad Prism 7.0 (GraphPad 
Software, La Jolla, CA). All data points are represented as means ± SEM. Two-tailed 
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experiments where multiple groups are compared with control, one-way ANOVA was 
used. P values < 0.05 were considered as statistically significant.  
 




Generation of arsenic trioxide resistant cell line: 
ATO resistant cells were generated by exposing the naïve NB4 cell line to low 
concentrations of ATO (50nM) for about 3 months. The concentration of ATO was 
gradually increased to 1µM over one year. The cells which survived and proliferated 
were termed as the “ATO tolerant persister cells” (ATO-TPs). The ATO-TPs were then 
subjected serially to limiting dilutions and single cell colony-forming unit formation on 
methylcellulose to isolate monoclonal resistant populations. We isolated three different 
clones, expanded and named them NB4EV-AsR1, NB4EV-AsR2, NB4EV-AsR3 
respectively based on the published norms of NB4 resistant cell line nomenclature19. 
The IC50 for ATO in these cell lines was 3.25μM, 3.4μM, and 2.88μM for NB4EV-AsR1, 
NB4EV-AsR2, and NB4EV-AsR3 respectively in contrast to naïve NB4 which was 
0.9µM (figure 1a). The viability of the in-house generated ATO resistant cell lines were 
not significantly affected by exposure to 2μM ATO in comparison to the sensitive cell 
line NB4 (figure 1b). The in-house generated ATO resistant cell lines were also 
significantly less sensitive to differentiation-inducing agent ATRA, similar to UF1 a 
known ATRA resistant cell line. Even the combination of ATO and ATRA (0.5uM and 
1uM respectively) did not induce a significant differentiation or cell death in the in-house 
generated ATO resistant cell lines when compared to naive NB4 cells (Figure 1c). Post 
exposure to ATRA(1uM) the induction of downstream targets of the RAR like TGM2, 
RARꞵ and RARꭤ transcripts were also found to be significantly less in the in-house 
generated ATO resistant cell lines in comparison to NB4 naive (supplementary figure 1).  
The doubling time of parental cell line NB4 was 28 hours, whereas for NB4EV-
AsR1 and NB4EV-AsR2 clones, it was 46 and 48 hours, respectively. Long term 
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reacquisition of ATO sensitivity (supplementary figure 2). Currently, the resistant cell 
lines have a stable resistant phenotype when grown with or without ATO. We have also 
observed that the ATRA resistant UF1 cell line is also cross-resistant to ATO with an IC-
50 of 4.9μM, an observation that has not been previously reported (Supplementary 
figure 3). 
 
ATO-resistant cell lines exhibit distinct cell surface markers and transporters: 
The ATO resistant cell lines were abnormal promyelocytes where the cell surface 
expression of the typical myeloid markers CD13 and CD33 was significantly reduced in 
comparison to the parental naïve cell line (figure 2a and Supplementary figure 4). The 
ATO efflux transporters such as AQP9, MRP4, ABCB6, and ABCA7 were significantly 
upregulated in the ATO resistant cell lines which mirrored in the reduced concentration 
of intracellular ATO (figure 2b and 2c).  
Since ATO induces the degradation of PML-RARA protein, we examined the sub 
cellular localization, transcript, and protein levels of PML / PML-RARA in the resistant 
cells in comparison to sensitive cell line NB4. In the immunofluorescence assay, we 
observed that the PML localized in the nucleus in a typical APL specific micro-speckled 
pattern in the NB4 cells whereas in the resistant cell lines we observed a similar micro-
speckled pattern but a decrease in the amount of nuclear PML (Figure 2d). There was 
also significant reduction in the levels of PML-RARA both at the transcript and protein 
levels in the resistant cell lines (figure 2e and 2f).  
 
In-house generated ATO resistant cell lines harbor additional cytogenetic and 
molecular aberrations:  
Cytogenetic analysis of both cell lines showed triploidy as well as the t(15;17). 
However, the NB4 EV-AsR1 showed additional cytogenetic abnormalities such as the 
deletion 5q, gain of chromosome 4 and loss of chromosome 22. The loss of the X 
chromosome as well as absence of the derivative chromosome 21 and the addition 16q 
which was seen in NB4 naïve was not observed in NB4 EV-AsR1 (supplementary table 
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As there are reports implicating the emergence of drug resistance-conferring 
somatic PML domain mutations in APL cells against ATO, we performed whole-exome 
sequencing on our in-house generated ATO resistant cell line NB4EV-AsR1 (as a 
representative of other ATO resistant clones) in comparison to the parental cell line NB4 
naïve and also on the UF1 cell line that was found to be resistant to ATO.   
Whole exome sequencing revealed that in comparison to NB4 naïve, a significant 
number of genes were mutated in the NB4EV-AsR1 and UF1 cell lines.  Based on the 
mutation frequency, we observed that in comparison to the NB4 naïve majority of the 
mutated genes in NB4EV-AsR1 belong to cell surface proteins especially mucins 
(MUC6, MUC5B, MUC4, MUC3A, MUC16), serine protease genes (PRSS1, PRSS3, 
PRSS3P2) and the ATO resistance-conferring PML B2 domain mutation (A216V). In 
contrast, the UF1 cell line showed a higher frequency of mutations involving MUC16, 
ITGB4, PRSS1, CUL7, CDH23, LTBP3, OBSCN, STAB1 genes (supplementary figure 
5) and did not have a PML B2 domain mutation. Further comparison of mutated genes 
in the resistant cell lines with the commonly observed mutations in the AML TCGA 
dataset revealed that in NB4EV-AsR1 with the exception of the PML B2 domain 
mutation, we did not observe any additional novel mutations over and above those 
described in the AML TCGA gene set. However, in UF1, there were additional novel 
mutations found in DNMT3A, TP53, RUNX1, IDH2, SMC3, ARID1B, ARID1A, and PML 
genes in addition to the known mutations in the AML TCGA gene set (figure 3a and 
supplementary file 1).   
Validation of PML and p53 mutation using sanger sequencing confirmed the 
existence of previously reported ATO resistance-conferring mutation A216V10 in the in-
house generated ATO resistant cell lines (including NB4EV-AsR2 and EV-AsR3). UF1 
had two intronic variations in the PML domain and was negative for A216V (figure 3b). 
We also noted that the existence of a p53 gain of function mutation (R248Q) in the in 
house generated ATO resistant cell line, which was also present in the parental naïve 
NB4 cell line. UF1 cell line had a point mutation (R196*) and a deletion of exon 10 of the 
p53 (figure 3c), which are reported to be pathogenic20.    
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As evident from drug withdrawal conditions and exome sequencing analysis, the 
observed ATO resistance was not explained by either a transient epigenetic poising or 
presence of a known acquired genetic mutation in the PML-B2 domain (absence of 
PML-B2 domain mutation in UF1). We next subjected NB4 naïve, NB4 EV-AsR1 and 
UF1 to gene expression profiling. We observed that 1717 genes in NB4 EV-AsR1 and 
6149 genes in UF1 were significantly upregulated (> 2-fold) in comparison to NB4 
naïve. The pathways significantly enriched for differentially expressed genes were cell 
survival, cell cycle, immune regulation, ABC transporters, glutathione metabolism, redox 
system, mitochondrial cellular respiration, and ubiquitin-proteasome degradation system 
(figure 4a). We also noted that the gene expression profile of the in-house generated 
ATO resistant cell line was similar to that of the relapsed APL patient’s gene profile (8 
unmatched newly diagnosed and relapsed APL) treated with front line ATO based 
regimens and previously reported by us21 (Figure 4b). Gene expression profiling 
revealed significant dysregulation of glycolytic and mitochondrial metabolism in the 
resistant cell line when compared to NB4 naïve (figure 4c).  
We also carried out a limited analysis of epigenetic modifications using chromatin 
immunoprecipitation combined with high-throughput sequencing (ChIP-Seq) for the 
H3k27ace, as an epigenetic marker of active enhancers and promoters and, H3k27me3 
as a marker for gene repression. In the in-house generated resistant cell line NB4EV-
AsR1 gene ontology enrichment on the H3k27ace mark of promoter regions showed 
significant enrichment for DNA damage, mitochondria, cell cycle and mRNA splicing 
clusters in comparison to the naïve NB4 cell line (supplementary file 2).  
We validated the finding by measuring the basal metabolic properties such as 
reactive oxygen species (ROS), antioxidant level, glucose uptake, and mitochondrial 
membrane potential (MMP), which are reported to be key factors in the mechanisms of 
action of ATO.  We observed that in comparison to naïve NB4 cells, ATO resistant cell 
lines (NB4EV-AsR1 and UF1) had low levels of basal ROS (Figure 5a), lower 
mitochondrial membrane potential (MMP) and low glucose uptake capacity (2-NBDG 
uptake, GLUT-1 and LDHA, both at transcript and protein level) in comparison to the 
naïve NB4 cells (figure 5c, d, and e). As expected, GSH levels were elevated in NB4EV-
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consistent with the above observation in comparison to newly diagnosed primary APL 
samples we observed significant downregulation of GLUT-1 and LDHA transcript levels 




ATO resistant APL cell lines are metabolically distinct in comparison to ATO 
sensitive cell line:  
     Glyco stress test revealed that the naïve NB4 cells had increased glycolysis 
where the basal extracellular acidification rate (ECAR) was significantly higher (figure 
6a) with increased oxygen consumption rate (OCR) (supplementary figure 7) in 
comparison to ATO resistant cell lines. 
To address the degree to which glycolysis is necessary for cell survival, we 
treated the naïve NB4 and ATO resistant cell lines with 2-Deoxy glucose (2-DG), a 
glucose analog that inhibits glycolysis via its action on hexokinases. We noted that 
naïve NB4 cell line viability was significantly affected in the presence of 2-DG, 
equivalent to the effect seen with 2µM of ATO. There was no evidence of an additive 
effect when these agents were combined (figure 6b). In contrast, the viability of the APL 
resistant cell lines and AML cell lines (U937 and THP-1; data not shown) was not 
significantly affected when 2-DG was used alone or in combination with ATO (figure 6b).  
 Having noted that glycolytic inhibition by 2-DG promoted apoptosis in NB4 cells 
comparable to that seen with ATO, we performed in-vivo glycolytic inhibition to 
understand the physiological relevance of glycolytic inhibition in the ATO sensitive 
transplantable APL mouse model. We observed that 2-DG or ATO as single agents 
reduced the leukemic burden in the peripheral blood (PB) and PML-RARA copy number 
at the end of 22 days to levels that were comparable and indistinguishable from each 
other (figure 6c).  
 
Heterogeneity of anti-apoptotic protein dependency of ATO resistant APL cell 
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We next assessed the mitochondria priming status of the ATO resistant cell lines 
by employing iBH3 profiling and their sensitivity to the BH3 mimetics. We observed a 
significant difference between the in-house ATO resistant cell lines and the parental cell 
line (independent of A216V). Neither a BCL-2 inhibitor (ABT-199 -Venetoclax-VEN) nor 
a BCL-XL inhibitor (A1331852) promoted apoptosis as a single agent in the parental 
and resistant cell lines whereas MCL-1 inhibitor (S63845) promoted apoptosis only in 
parental NB4 naïve and NB4EV-AsR2 (figure 7a). The sensitivity to the BH3 mimetics 
correlated with their basal BH3 profiling (figure 7b). 
 
Combination of glycolytic inhibitor (ATO) and mitocans promoted apoptosis in 
the ATO resistant cell lines:  
  We then evaluated the effect of mitochondrial OXPHOS uncoupler on the ATO 
resistant promyelocytic and non-promyelocytic AML cell lines. The viability of ATO 
resistant cell lines was not affected significantly when treated with the mitochondrial 
OXPHOS un-coupler FCCP as a single agent, whereas in combination with ATO, the 
viability was significantly reduced in NB4EV-AsR1(harbors A216V mutation; resistant to 
BCL-2 and MCL-1 inhibition); NB4EV-AsR2 (harbors A216V mutation, and sensitive to 
MCL-1inhbition), UF1 cell line (A216V negative, sensitive to BCL-2 and MCL-1 
inhibition) (Figure 7c). A similar effect was observed in non-M3 AML cell lines, U937 
and THP-1 (resistant to BCL-2 inhibition and ATO whereas sensitive to MCL-1; 
Supplementary figure 8). We observed that the ATO resistant APL and AML cell lines, 
were significantly different in their metabolic preferences for their survival from the ATO 
sensitive NB4 naïve cell line and by targeting this difference we were able to overcome 
the resistance independent of the existence of the PML-B2 domain mutation and their 
anti-apoptotic protein dependency.  Blocking mitochondrial respiration in combination 
with ATO therefore can enhance cell death in ATO and ATRA resistant APL cell lines 
and non-M3 AML cell lines. However, this combination had significant off target effects 
on the normal peripheral blood mononuclear cells and further evaluation for compounds 
that selectively target the leukemic cell’s mitochondrial respiration is needed for these 
observations to be translated to the clinic.   









      The study highlights that in comparison to the existing ATO resistant APL cell 
lines22,23 our in-house generated ATO resistant cell lines are stable, well-characterized 
at the genomic levels and they also possess the well-known ATO resistance-conferring 
mutation A216V in the B2 domain of the PML-RARA oncoprotein. These ATO resistant 
cell lines are observed to be less sensitive to differentiation with ATRA and to the 
combination therapy of ATO and ATRA and are hence an excellent tool to evaluate 
additional mechanisms that could contribute to drug resistance. We also noted that the 
UF1 APL cell line was resistant to ATO (not been previously reported) but did not have 
the well-defined PML-RARA B2 domain mutation giving us an opportunity to study ATO 
resistance with and without PML-RARA B2 domain mutations.   
In comparison to the naïve NB4, in house generated ATO resistant cell lines 
overexpressed ATO efflux transporters such as AQP9, MRP4, and ABCA7, which 
correlated with their inability to accumulate intracellular ATO. This phenomenon was not 
observed in primary blasts from relapsed APL patients previously treated with ATO in 
comparison to newly diagnosed21. The possibility of efflux transporters as a protective 
mechanism of ATO resistance cannot be excluded in the clinic and needs further 
evaluation.  
We noted the presence of a somatic mutation in the B2 domain of the PML gene 
in our in-house generated ATO resistant cell line that has been reported to confer 
resistance to ATO. It is important to note that these mutations are acquired post ATO 
treatment, and none of the APL cell lines or relapsed APL patients prior to ATO therapy 
had the B2 domain mutation24. The in-house resistant cell lines did not acquire 
additional mutations in p53 gene which has been reported to be critical for the 
regulation of NB formation and ROS generation. The observation suggests that the 
reduction in the PML micro-speckled pattern formation and low ROS levels are 
independent of p53 status in these cell lines. The cellular redox system of the resistant 
cell lines was found to be significantly altered in these cell lines having lower ROS 
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and stemness like properties25.  This was further corroborated by the observation of low 
ECAR and OCR status of the resistant cell lines 26.  
ATO sensitive cell line NB4 naïve was observed to be more reliant on the 
Warburg effect for their survival and proliferation, and their viability was significantly 
affected by a glycolytic inhibitor (2-DG). In an in-vivo APL model, 2-DG significantly 
reduced the leukemic burden comparable to the standard of care (ATO). This further 
supports our observation that the naïve ATO sensitive APL cells survival could be 
targeted by glycolytic inhibition. Based on the recognized inhibitory effect of ATO on the 
glycolytic pathway17 this could also be an important mechanism by which ATO induces 
apoptosis in malignant promyelocytes. In contrast, the ATO resistant APL and AML cell 
lines were mainly dependent on OXPHOS for their survival. However, unlike NB4 naïve 
cells the ATO resistant and AML cell lines had greater metabolic plasticity to switch 
between glycolysis and the OXPHOS when one is inhibited but were susceptible to a 
combination of ATO and mitocans, this susceptibility was independent of their PML B2 
domain mutation status and their anti-apoptotic protein dependency. It is well known 
that A216V mutation alters the ATO binding on the B2 domain of the PML-RARA 
oncoprotein, the observed combinatorial effect of ATO in combination with mitocan on 
the resistant cell lines is hence likely to be due to the inhibitory effect of ATO on the 
glycolytic pathway13,27.   
   Taken together, our work demonstrates that ATO resistance is multi-factorial and 
is not limited to presence or absence of either PML or p53 mutations. The in-house 
generated ATO resistant cell line would be a useful model to further evaluate 
mechanisms of resistance in leukemia. Targeting the metabolic adaptations seen in 
ATO resistant cell lines has the potential to overcome such resistance.  Inhibiting 
mitochondrial respiration in combination with ATO could overcome ATO resistance and 
translating this approach to the clinic both in relapsed APL and in the treatment of newly 
diagnosed AML needs to be explored further. While the combination of ATO and FCCP 
was observed to be non-selective, there are a number of FDA approved drugs used in 
the clinic that have the property to selectively inhibit mitochondrial respiration in cancer 
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leukemia28. Our data also draws attention to possible severe off target toxicity of such 
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Figure Legends:  
 
Figure 1: Generation of ATO resistant cell lines. a) NB4 naïve parental cell line was 
exposed to 50nM of ATO for three months, and the concentration was gradually 
increased to 1µM ATO over a period of one year until they sustained and proliferated. 
Limiting dilutions and colony-forming unit assay were performed to generate mono 
clones of the resistant cell lines. b) The bar graph represents the percentage of viable 
cells post 48 hours of 2µM ATO. c)  Representative dot plots and stacked bars 
(summarizes the dot plots results) NB4 and resistant cell lines were treated with 0.5µM 
and 1uM of ATRA for 72hrs as single agents and in combination with 2uM ATO, and the 
percentage of differentiation was measured by the surface expression of CD11b and 
dead cells were measured by 7AAD. Graphs and statistical parameters were generated 
from three independent experiments. *p≤0.05; **p≤0.01; ***p≤0.001; ***p≤0.0001. 
 
 
Figure 2: Heterogeneity in the cell surface marker and transporters expression of the 
ATO resistant cell line in comparison to parental cell line: a) CD13 and CD33 surface 
expression of ATO resistant cell lines in comparison to NB4 naïve. b) Relative mRNA 
levels of ATO influx gene (ABCA1) and efflux transporters genes (ABCA7, AQP9, 
MRP4, and ABCB6) in the in-house generated ATO resistant cell lines compared to 
NB4 naïve which is normalized to one. c) Intracellular ATO levels in NB4 naïve and 
ATO resistant cell lines post 24 hours of 0.5µM ATO treatment. d)Fluorescent 
microscopic image of the PML (RED) in NB4 naïve and ATO resistant cell lines 
displaying nuclear body formation and micro speckled pattern (magnification 63x – oil 
immersion) e) PML-RARA transcripts in the NB4 naïve and in-house generated ATO 
resistant cell lines f) Immunoblots of the PML-RARA fusion protein levels in NB4 naïve 
and ATO resistant cell lines. All error bars represent the mean  SEM of three 
independent experiments. *p≤0.05; **p≤0.01; ***p≤0.001; ***p≤0.0001. 
 
 
Figure 3: Whole-exome sequencing reveals changes in the ATO resistant cell lines at 
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in AsR1 and UF1, and the graph represents the novel mutations (only found in resistant 
cell lines) and their mutation frequency. B) Sanger sequencing showing the existence of 
PML – A216V in the in-house generated ATO resistant cell line and not in the UF1 and 
parental cell line NB4 naïve. c) Mutations observed in the p53 gene of ATO resistant 
and sensitive cell lines. 
 
 
Figure 4: Gene expression analysis of the ATO resistant cell lines reveals dysregulation 
of cellular metabolism. a) Pie chart representing the dysregulated genes in the in-house 
generated ATO resistant cell line NB4 EV-AsR1 and UF1 in comparison to parental cell 
line NB4 naïve. b) Heatmap highlighting gene signature of NB4 naïve (duplicate) in-
house generated ATO resistant cell line (duplicate) and the 8 unmatched newly 
diagnosed and relapsed APL samples (primary cells data previously reported and 
adapted from Ezhilarasi Chendamari., et.al., PloS one 2015). c) Heatmap representing 
NB4 naïve, ATO resistant cell line NB4 EV-AsR1 and UF1 cell lines genes involved in 
the glycolytic and mitochondrial metabolism. 
 
 
Figure 5: ATO resistant cell lines are metabolically distinct. a) Baseline total reactive 
oxygen species were measured using redox-sensitive dye (cell ROX Green) by flow 
cytometry. b) Baseline protein thiols was measured as an indicative of antioxidant using 
OPT (Phthaldialdehyde) and median fluorescence intensity are represented as bar 
graphs. c) Mitochondria membrane potential of the resistant cell lines were measured 
using JC-1 d) Glucose uptake was measured using a fluorescent analogue of 2- deoxy 
glucose and represented as relative mean fluorescence intensity. GLUT-1 and LDHA 
transcripts (e) and protein (f) levels of NB4 naïve, NB4 EV-AsR1 and UF1 cell lines. All 
error bars represent the means  SEM of three to four independent experiments. 
*p≤0.05; **p≤0.01; ***p≤0.001; ***p≤0.0001. 
 
Figure 6: ATO resistant cells are metabolically heterogeneous and in vivo effect of 




 http://ashpublications.org/bloodadvances/article-pdf/doi/10.1182/bloodadvances.2021005300/1827425/bloodadvances.2021005300.pdf by guest on 13 O
ctober 2021
 
extracellular acidification rate (ECAR) and glycolytic potential of NB4 naïve, NB4 EV-
AsR1 and UF1 cell lines were assessed in real time using seahorse extracellular flux 
analyzer. b) Viability of the sensitive and resistant cell lines post 48 hours of glycolytic 
inhibitor ATO and 2-DG (ATO = 2µM; 2-DG = 5mM; 48 hours; n=4). All error bars 
represent the means  SEM of four independent experiments. *p≤0.05; **p≤0.01; 
***p≤0.001; ***p≤0.0001. c) Schematic representation of the APL transplantable mouse 
model and treatment plan. Mice were euthanized on day 22 and examined for the 
presence of leukemic cells as CD117+Gr1+ cells in peripheral blood, and PML-RARA 
transcript levels in bone marrow.  
 
 
Figure 7: Mitocans synergize with ATO to promote apoptosis in the ATO resistant cell 
lines.  a)  Viability of NB4 and in-house generated ATO resistant cell lines to BH3 
mimetics (n=5). b) Intracellular BH3 profiling of ATO resistant and sensitive cells (n=3) 
measured using intracellular cytochrome-c retention. c) Viability of the sensitive and 
resistant APL and non-APL cell lines treated with OXPHOS uncoupler FCCP in 
combination with ATO.  ATO = 2µM; FCCP =10µM and BH3 mimetics = 250nM; 48 
hours.  All error bars represent the means  SEM of four independent experiments. 
*p≤0.05; **p≤0.01; ***p≤0.001; ***p≤0.0001. (ABT-199 – Venetoclax; S63845 - MCL-1 















































 http://ashpublications.org/bloodadvances/article-pdf/doi/10.1182/bloodadvances.2021005300/1827425/bloodadvances.2021005300.pdf by guest on 13 O
ctober 2021
